New Haven, Conn.-based Yale University is partnering with pharmaceutical company Boehringer Ingelheim to launch a Biomedical Data Science Fellowship program aimed at innovating drug discovery.
A May 10 news release said the fellowship will help clinicians and pharmaceutical companies identify potential new pathways for treatment and eradication of diseases.
Five things to know:
- The three-year fellowship will give post-doctoral researchers access to Yale's computational resources, biomedical data repositories and faculty expertise. Fellows will also have access to Boehringer Ingelheim's corporate labs, scientists and executives.
- Applicants are invited to submit research proposals for consideration by June 15. Three fellowships will be awarded each year until nine are selected in the first five years.
- Selected fellows will be jointly mentored by Yale researchers and Boehringer Ingelheim.
- The program will be based at the Yale Center for Biomedical Data Science, and fellowship training will begin Sept. 1.
- The program aims to harness data science to transform drug discovery and development.